Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15508447rdf:typepubmed:Citationlld:pubmed
pubmed-article:15508447lifeskim:mentionsumls-concept:C0855002lld:lifeskim
pubmed-article:15508447lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:15508447lifeskim:mentionsumls-concept:C0078257lld:lifeskim
pubmed-article:15508447lifeskim:mentionsumls-concept:C0868928lld:lifeskim
pubmed-article:15508447lifeskim:mentionsumls-concept:C0205420lld:lifeskim
pubmed-article:15508447lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:15508447pubmed:issue10lld:pubmed
pubmed-article:15508447pubmed:dateCreated2004-10-28lld:pubmed
pubmed-article:15508447pubmed:abstractTextCase 1:A 62-year-old man, who had undergone right upper lobectomy for lung squamous cell carcinoma (pT2pN2M0, stage IIA) 4 months earlier, was diagnosed as mediastinal lymph node recurrence by chest CT. Case 2: A 63-year-old woman, who had undergone right middle-lower lobectomy for lung squamous cell carcinoma (pT2pN1M0, stage IIB) 16 months earlier, was diagnosed as hilar lymph node recurrence by chest CT. Both patients underwent radiochemotherapy with 2 cycles of cisplatin (CDDP) 80 mg/m2 on day 1 and vinorelbine (VNR) 15 mg/m2 on day 1 and another day (day 8-16), and concurrent radiation (60 Gy/30 fr) for mediastinum. After this treatment, a partial response (PR) in case 1 and a complete response (CR) in case 2 were achieved, and neither patient showed any relapse after 3 years of the treatment. Adverse reactions were grade 3 neutropenia in both patients and transient hemiparalysis in case 2. Concurrent radiochemotherapy with cisplatin and vinorelbine is considered effective without serious side effects for postoperative recurrence in localized mediastinal lymph nodes of non-small-cell lung cancer.lld:pubmed
pubmed-article:15508447pubmed:languagejpnlld:pubmed
pubmed-article:15508447pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15508447pubmed:citationSubsetIMlld:pubmed
pubmed-article:15508447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15508447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15508447pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15508447pubmed:statusMEDLINElld:pubmed
pubmed-article:15508447pubmed:monthOctlld:pubmed
pubmed-article:15508447pubmed:issn0385-0684lld:pubmed
pubmed-article:15508447pubmed:authorpubmed-author:NakamuraShini...lld:pubmed
pubmed-article:15508447pubmed:authorpubmed-author:YanoHiroshiHlld:pubmed
pubmed-article:15508447pubmed:authorpubmed-author:IwazawaTakash...lld:pubmed
pubmed-article:15508447pubmed:authorpubmed-author:MondenTakushi...lld:pubmed
pubmed-article:15508447pubmed:authorpubmed-author:KanohToshiyuk...lld:pubmed
pubmed-article:15508447pubmed:authorpubmed-author:OhnishiTadash...lld:pubmed
pubmed-article:15508447pubmed:authorpubmed-author:MatsuiShigeoSlld:pubmed
pubmed-article:15508447pubmed:authorpubmed-author:TonoTakeshiTlld:pubmed
pubmed-article:15508447pubmed:authorpubmed-author:NakanoYoshiak...lld:pubmed
pubmed-article:15508447pubmed:authorpubmed-author:KimuraYutakaYlld:pubmed
pubmed-article:15508447pubmed:issnTypePrintlld:pubmed
pubmed-article:15508447pubmed:volume31lld:pubmed
pubmed-article:15508447pubmed:ownerNLMlld:pubmed
pubmed-article:15508447pubmed:authorsCompleteYlld:pubmed
pubmed-article:15508447pubmed:pagination1543-6lld:pubmed
pubmed-article:15508447pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15508447pubmed:meshHeadingpubmed-meshheading:15508447...lld:pubmed
pubmed-article:15508447pubmed:meshHeadingpubmed-meshheading:15508447...lld:pubmed
pubmed-article:15508447pubmed:meshHeadingpubmed-meshheading:15508447...lld:pubmed
pubmed-article:15508447pubmed:meshHeadingpubmed-meshheading:15508447...lld:pubmed
pubmed-article:15508447pubmed:meshHeadingpubmed-meshheading:15508447...lld:pubmed
pubmed-article:15508447pubmed:meshHeadingpubmed-meshheading:15508447...lld:pubmed
pubmed-article:15508447pubmed:meshHeadingpubmed-meshheading:15508447...lld:pubmed
pubmed-article:15508447pubmed:meshHeadingpubmed-meshheading:15508447...lld:pubmed
pubmed-article:15508447pubmed:meshHeadingpubmed-meshheading:15508447...lld:pubmed
pubmed-article:15508447pubmed:meshHeadingpubmed-meshheading:15508447...lld:pubmed
pubmed-article:15508447pubmed:meshHeadingpubmed-meshheading:15508447...lld:pubmed
pubmed-article:15508447pubmed:meshHeadingpubmed-meshheading:15508447...lld:pubmed
pubmed-article:15508447pubmed:meshHeadingpubmed-meshheading:15508447...lld:pubmed
pubmed-article:15508447pubmed:meshHeadingpubmed-meshheading:15508447...lld:pubmed
pubmed-article:15508447pubmed:year2004lld:pubmed
pubmed-article:15508447pubmed:articleTitle[Two cases of recurrent lung cancer successfully treated with concurrent radiochemotherapy with vinorelbine plus cisplatin].lld:pubmed
pubmed-article:15508447pubmed:affiliationDept of Surgery, NTT West Osaka Hospital.lld:pubmed
pubmed-article:15508447pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15508447pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:15508447pubmed:publicationTypeCase Reportslld:pubmed